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Abstract
Background: To clarify the relationship between the probability of prostate cancer scaled using a 5-point Likert
system and the biological characteristics of corresponding tumor foci.
Methods: The present study involved 44 patients undergoing 3.0-Tesla multiparametric MRI before laparoscopic
radical prostatectomy. Tracing based on pathological and MRI findings was performed. The relationship between
the probability of cancer scaled using the 5-point Likert system and the biological characteristics of corresponding
tumor foci was evaluated.
Results: A total of 102 tumor foci were identified histologically from the 44 specimens. Of the 102 tumors, 55
were assigned a score based on MRI findings (score 1: n = 3; score 2: n = 3; score 3: n = 16; score 4: n = 11 score 5:
n = 22), while 47 were not pointed out on MRI. The tracing study revealed that the proportion of >0.5 cm3
tumors increased according to the upgrade of Likert scores (score 1 or 2: 33 %; score 3: 68.8 %; score 4 or 5: 90.9
%, χ2 test, p < 0.0001). The proportion with a Gleason score >7 also increased from scale 2 to scale 5 (scale 2: 0 %;
scale 3: 56.3 %; scale 4: 72.7 %; 5: 90.9 %, χ2 test, p = 0.0001). On using score 3 or higher as the threshold of
cancer detection on MRI, the detection rate markedly improved if the tumor volume exceeded 0.5 cm3 (<0.2 cm3:
10.3 %; 0.2-0.5 cm3: 25 %; 0.5-1.0 cm3: 66.7 %; 1.0 < cm3: 92.1 %).
Conclusions: Each Likert scale favobably reflected the corresponding tumor’s volume and Gleason score. Our
observations show that “score 3 or higher” could be a useful threshold to predict clinically significant carcinoma
when considering treatment options.
Background
In the treatment of prostate carcinoma, one of the
major disadvantages of preoperative MRI is the lack of
a standardized reporting system. Sometimes, the report
may be written in a narrative manner, making it diffi-
cult to compare studies from different centers. Re-
cently, the European Society of Urogenital Radiology
recommended the use of the MR Prostate Imaging
Reporting and Data System (PI-RADS) [1], and the
Prostate Diagnostic Imaging Consensus Meeting panel
proposed using 5-point Likert scaling [2]. Regarding
the 5-point Likert scaling, it was the most commonly
used method in previous clinical studies [3–5]. In order
to promote widespread use of the 5-point Likert scaling
system in daily clinical practice, we consider that stud-
ies comparing the probability of cancer scaled using the
5-point Likert system and the biological characteristics
of correspondig tumor foci should be accumulated, and
the results should be shared among surgeons and radi-
ologists as a common language.
In the present study, in order to gain further insight
into the association between tumor-foci characteristics
and the 5-point Likert score, we performed a detailed
comparison between all small cancerous foci on whole-
mount histopathology and radiological findings accord-
ing to 5-point Likert scaling using the recent 3.0-Tesla
multiparametric MRI.
Methods
The study protocol was approved by the institutional re-
view board of Hokkaido University Hospital, and patient
consent was not deemed necessary because data were
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obtained from medical charts and patient identifying in-
formation was anonymized before analysis.
Patients
Between June 2009 and April 2013, 80 patients with
localized prostate carcinoma underwent laparoscopic
radical prostatectomy (LRP). Of these, 56 patients
underwent 3.0-Tesla multiparametric MRI before sur-
gery. Excluding 12 patients due to a lack of dynamic
contrast-enhanced (DCE) MRI (n = 5), susceptibility arti-
facts on diffusion- weighted imaging (DWI) (n = 4), or
sequence differences (n = 3), the final study population
consisted of 44 patients. No prior radiation therapy and/
or androgen deprivation therapy was performed in our
cohort.
MRI technique
MRI was performed before biopsy in 6 patients, and the
interval between biopsy and MRI was a median of 99
days (range: 27–855) in the remaining 38 patients.
Patients underwent MRI with a 3.0-T scanner (Achieva
3.0-T TX series R3.21; Philips Medical Systems, Best, the
Netherlands) and a pelvic phased-array coil (32-channel
SENSE Torso/Cardiac Coil). No endorectal coil was
used. The slice thickness of all the sequences was 3 mm.
The following MR sequences were obtained: axial T1-
weighted image (T1WI), axial T2-weighted image
(T2WI), axial, sagittal, and coronal fat-suppressed T2WI,
axial DWI, and DCE MRI. DCE MRI was performed in
the axial plane with one pre-contrast and four post-
contrast dynamic series after the intravenous administra-
tion of gadolinium-based contrast material at a dose of
0.1 mmol per kilogram body weight and subsequent
flushing with standardized 20-mL saline. The apparent
diffusion coefficient (ADC) values were calculated from
two DWI scans acquired with b = 0 and 2,000 s/mm2,
and ADC maps were then rebuilt by calculating the
ADC values in each pixel of each slice. In the present
study, we did not perform any bowel preparation, or ad-
minister any agent to suppress bowel peristalsis.
Image analysis
For this retrospective analysis, all MR images were
reviewed in consensus by two radiologists with 13 and 5
years’ experience in prostate MRI. Both readers were
aware that the patients had prostate cancer documented
by biopsy and had undergone LRP, but were blind to all
other clinical data. On pre-contrast DCE MRI, high-
signal-intensity areas were considered hemorrhagic after
prostate biopsy. On T2WI, a finding suggesting prostate
cancer was defined as a hypointense area in the prostate
compared to the adjacent parenchyma, excluding an area
of hemorrhage. In the case of a wedge-shaped hypoin-
tense area without a mass effect around the adjusting
prostatic tissue, we suspected chronic prostatitits rather
than prostatic cancer, considering the results of other se-
quences together. On DWI, it was defined as a focal hy-
perintense area at b = 2,000 s/mm2 of DWI, with a low
focal ADC value compared to that of the adjacent nor-
mal parenchyma on ADC mapping. On DCE-MRI, it
was defined as an early enhancing area in the prostate
compared to adjacent normal parenchyma. In the case
of biopsy–related hemorrhage, we tried to identify an
enhanced lesion by carefully comparing pre and post im-
ages. The likelihood of the presence of prostate cancer
was determined based on an overall combination of the
findings from T2WI, DWI, and DCE-MRI using a Likert
scale between 1 and 5 (1, very low level of suspicion; 2,
low level of suspicion; 3, equivocal; 4, cancer probable;
5, definitely cancer).
Pathology
Following LRP, the specimens were fixed overnight in 10 %
neutral buffered formaldehyde. After staining of the sur-
face, each specimen was cut into transverse 5-mm-thick
slices, vertical to the dorsorectal surface, and the apex and
base were sagittally sectioned. After pathological evalu-
ation, all tumor foci were mapped on the macroscopic
photographs. For all LRP specimens, the primary and sec-
ondary Gleason grades as well as the combined Gleason
score were recorded. The T-category was defined accord-
ing to the 2009 TNM classification.
For the present study, tumor areas in the macroscopic
photographs were traced and measured using computer
planimetry software (Image J, free software). If the dis-
tance between two tumor foci was greater than 5 mm,
they were considered separate. The tumor volume was
calculated by multiplying the total tumor surface area by
the section thickness (5 mm). For analysis, a shrinkage
factor of 1.15 was considered [6]. When the Gleason
score in each focal lesion had not been described in the
original pathological report, we evaluated it (HF). There-
after, tracing based on pathological mapping and MRI
findings was performed jointly by three of the authors
(TH, TA, and FK; Fig. 1).
Statistical analysis
Analyses were performed with JMP® version 11 (SAS
Institute, Japan). We used the χ2 test to compare cat-
egorical characteristics among the groups. Univariate
and multivariate logistic regression analyses were used
to indentify characteristics associated with the visibility
of cancerous lesions on 3-Tesla MRI. A p-value <0.05
was considered significant.
Results
Clinical and pathological characteristics of the 44 patients
were as follows: mean age, 67.1 years, median age, 68
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years (range: 52–77); median PSA, 6.91 ng/mL (range:
1.75–37.6); median time between MRI and LRP, 10 days
(range: 1–164). Thirty-one patients were in stage pT2 and
13 in pT3. Regarding the node status, all patients showed
pN0. Table 1 summarizes the characteristics of tumor foci.
A total of 102 tumor foci were identified histologically
from the 44 LRP specimens. The median tumor volume
was 0.386 cm3 (range: 0.0023–14.0) after shrinkage cor-
rection. The Gleason score distribution was 6 in 49, 7 in
40, and 8–9 in 13.
Of the 102 tumors, 55 were assigned a score based on
MRI findings (score 1: n = 3; score 2: n = 3; score 3: n = 16;
score 4: n = 11 score 5: n = 22) and 47 were not pointed
out on MRI. Figure 2 shows a mosaic plot of the relation-
ship between the tumor volume and each assigned Likert
score. The proportion of >0.5 cm3 tumors increased with
the upgrade of Likert scores (score 1 or 2: 33 %; score 3:
68.8 %; score 4 or 5: 90.9 %, χ2 test, p < 0.0001). The me-
dian tumor volume according to each scale was 0.459 cm3
(range: 0.0696–0.597) for scale 1, 0.267 cm3 (range:
0.0558–0.954) for scale 2, 0.816 cm3 (range: 0.0023–5.79)
for scale 3, 1.53 cm3 (range: 0.332–7.93) for scale 4, and
2.34 cm3 (range: 0.065–14.0) for scale 5. Figure 3 shows a
mosaic plot of the relationship between the Gleason score
and each assigned Likert score. The proportion with a
Gleason score >7 also increased from score 2 to score
5 (scale 2: 0 %; scale 3: 56.3 %; scale 4: 72.7 %; scale
5: 90.9 %, χ2 test, p = 0.0001).
On the other hand, 95 areas were pointed out and
scaled on image review by the 2 radiologists. Tracing be-
tween pathological mapping and MRI findings revealed
that 10 areas pointed out on MRI were overlapping on
pathological mapping. Of the 85 non-overlapping areas,
the positive predictive value for the diagnosis of cancer
according to each score was 20 % (2/10) for score 1, 23.5 %
(4/17) for score 2, 75 % (15/20) for score 3, 73.3 % (11/15)
for score 4, and 95.7 % (22/23) for score 5. The positive
predictive value was 82.8 % (48/58) for score >3.
Fig. 1 A 74-year-old patient with a PSA level of 16.08 ng/mL. A T2-weighted image (T2WI) demonstrates decreased signal intensity lesions in both
lobes (a). These lesions show a focally increased signal intensity on diffusion-weighted (DWI, b) and dynamic contrast-enhanced (DCE, c) MRI.
Using the five-point Likert scale, the two readers assigned a score of 5 to both lesions. On the other hand, the small tumor foci pointed out by
the blue arrow in the histology (d) was not pointed out on MRI reading
Table 1 Summary of characteristics of tumor foci
Tumor location, n
Peripheral zone 85
Central/Transition zone only 17
Tumor volume, cm3 Median, 0.386
(range, 0.0023–14.0)
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Based on our current observations, the assigned
scores of 3–5 were treated as visible cancerous lesions
on MRI in the subsequent analyses. Figure 4 shows a
mosaic plot regarding tumor visibility on MRI in ac-
cordance with the tumor volume. After the tumor vol-
ume exceeded 0.5 cm3, the detection rate on MRI
markedly improved (0.5–1.0 cm3: 6/9, 66.7 %, 1.0 < cm3:
35/38, 92.1 %). Overall, the sensitivity for cancer detec-
tion was 87.2 % (41/47) for tumors larger than 0.5 cm3.
Table 2 shows the results of multivariate analysis to
identify the characteristics associated with visibility on
3-T MRI. The tumor volume and Gleason sum were
significant factors on univariate analysis. In the multi-
variate model, only the tumor volume remained
significant.
Discussion
The usefulness of MRI for imaging prostate carcinoma
has already been recognized [7]. On the other hand,
most radiologists would agree that the diagnosis and
localization of carcinoma are not always easy due to coex-
isting hyperplasia, prostatitis, or bleeding, and it is some-
times difficult to fill in medical records in a “black or
white” manner. Recently, two scoring systems were rec-
ommended: PI-RADS and the Likert scale. The PI-RADS
system uses multi-parametric techniques including T2-
weighted imaging, DCE MRI, and DWI, and a score from
one to five is given according to each variable [1]. There-
fore, total scores range from 3 to 15, and a threshold of 8
or greater, or 9 or greater, has been used as a cutoff for
cancer detection in previous studies [8, 9]. Regarding
Fig. 2 Mosaic plot of relationship between tumor volume and each assigned Likert score. The proportion of >0.5 cm3 tumors increased
according to the upgrade of Likert scores (χ2 test, p < 0.0001)
Fig. 3 Mosaic plot of relationship between Gleason score and each assigned Likert score. The proportion of Gleason score >7 also increased from
scale 2 to scale 5 (χ2 test, p = 0.0001)
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the Likert system, a rating from 1 to 5 was assigned
based on the overall impression of MRI findings, and a
threshold of 3 or higher was typically used in previous
studies [3–5]. In the present study, we performed a
close comparison between all small cancerous foci on
whole-mount histopathology and radiological findings
according to 5-point Likert scaling using the recent
3.0-Tesla multiparametric MRI. We observed that the
proportion of >0.5 cm3 tumors increased according to
the upgrade of Likert scores (score 1 or 2: 33 %; score
3: 68.8 %; score 4 or 5: 90.9 %, χ2 test, p < 0.0001), and
the proportion of those with Gleason score >7 also in-
creased from score 2 to score 5 (score 2: 0 %; score 3:
56.3 %; score 4: 72.7 %; 5: 90.9 %, χ2 test, p = 0.0001).
Our observations confirmed that a threshold of 3 or
higher is very helpful for clinicians when considering
the possibility of significant cancer, denoting >0.5 cm3
or Gleason score >7 tumors. Although we did not as-
sess PI-RADS data or inter-observer variability in
scoring, Renard-Penna et al. reported favorable interob-
server agreement between the Likert scale (κ = 0.80)
and PI-RADS system (κ = 0.73) [8].
Regarding detectability on MRI according to the can-
cer volume, Ikonen S et al. previously reported that, with
the use of endorectal coil 1.5-T MRI (T2-weighted), the
rate of detecting carcinoma foci smaller than 5 mm was
5 %, but it was 89 % for those larger than 10 mm [10].
Roethke MC et al. reported similar results, whereby they
were able to visualize 0/56 lesions with a size of <0.3 cm
(0 %), 4/116 (3 %) between 0.3 and 0.5 cm, 22/169 (13
%) between 0.5 and 1 cm, 61/136 (45 %) between 1 and
2 cm, and 50/56 (89 %) >2 cm using endorectal coil 1.5-
T MRI (T2-weighted) [11]. Villers et al. also reported
that sensitivity, specificity, and positive and negative pre-
dictive values for cancer detection by 1.5-T pelvic
phased-array coil MRI were 90, 88, 77, and 95 %, re-
spectively, for foci larger than 0.5 cc [12]. In the present
study, the positive predictive value for a diagnosis of
cancer based on MRI findings was 75 % (15/20) for
score 3, 73.3 % (11/15) for score 4, and 95.7 % (22/23)
for score 5. Using a threshold of 3 or greater to indicate
probable cancer, the detection rate on MRI markedly
improved (0.5–1.0 cm3: 6/9, 66.7 %, 1.0 < cm3: 35/38,
92.1 %) when the tumor foci volume exceeded 0.5 cm3.
Fig. 4 Mosaic plot of relationship between tumor visibility on 3-Tesla MRI and range of tumor volume
Table 2 Logistic regression analysis of analysis of factors associated with visibility on 3-T MRI
Univariate analysis Mutivariate analysis
Variables analyzed No. of tumor foci Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
Age 102 1.03 (0.976–1.10) 0.266
PSA 102 1.01 (0.957–1.07) 0.647
Tumor location
Central/Transition zone only 17 0.954 (0.329–2.73) 0.929
Peripheral zone 85 1
Tumor volume 102 8.53 (3.85–24.3) <0.0001 9.24 (3.60–31.8) <0.0001
Gleason sum 102 3.47 (1.89–7.06) <0.0001 0.871 (0.321–2.24) 0.778
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Overall, sensitivity for cancer detection was 87.2 % (41/
47) for tumors larger than 0.5 cm3, and the positive
predictive value was 82.8 % (48/58) for score >3. Multi-
variate analysis identified only the tumor volume as be-
ing significantly correlated with visibility on MRI.
Because 1 cm in diameter represents a sphere of 0.5
cm3, we consider that, although the detection limit of
small foci was the same as that using endorectal coil or
pelvic phased-array coil 1.5-T MRI, modern 3.0-Tesla
multiparametric MRI offers a more sophisticated image
of the prostate and can clearly visualize most tumors
larger than 0.5 cm3. In other words, 3.0-Tesla can iden-
tify clinically significant disease in terms of a tumor
volume >0.5 cm3. In contrast, it can barely detect tu-
mors with a volume of less than 0.5 cm3 regardless of
the Gleason score. In the current study, an endorectal
coil was not used, and we, therefore, did not generate
data on how an endorectal coil can aid in tumor depic-
tion. Previously, Park BK et al. and Sosna J et al. re-
ported that 3.0-T pelvic phased-array MRI could
produce an image equivalent to 1.5-T endorectal MRI
[13, 14]. Kim BS et al. also reported that the staging
ability was not significantly different between 3.0-T pel-
vic phased-array MRI and 3.0-T endorectal coil MRI
[15]. In contrast, Turkbey et al. recently reported that
the combined use of a nonendorectal coil and an
endorectal coil led to the detection of more cancerous
foci than the sole use of a nonendorectal coil [16]. At
present, we consider that patients’ discomfort and the
additional cost are drawbacks to the use of an endorec-
tal coil, and preoperative evaluation with a nonendorec-
tal coil would be more acceptable universally in daily
clinical practice.
As described above, the positive predictive value for
a diagnosis of cancer based on MRI findings was 75 %
(15/20) for score 3, 73.3 % (11/15) for score 4, and 95.7 %
(22/23) for score 5. Conversely, 10 lesions assigned a
score >3 (3: n = 5; 4: n = 4; 5: n = 1) were false-
positive findings on MRI. After the analysis, we con-
vened a meeting with the pathologists to discuss the
cause of these false-positive findings, and found that
the most frequent histological finding was inflamma-
tion (n = 7), and abscess formation was also noted in
one case (data not shown). It would be optimal to
perform MRI before prostate biopsy to minimize
these artifacts. It has been established that an interval
of at least eight weeks is needed to minimize artifacts
due to prostate biopsy [17]. Regarding the 6 foci
greater than 0.5 cm3 which were missed on MRI
(Fig. 3), a strong background due to hemorrhage (n =
1), an anterior TZ location (n = 1), an apex location
(n = 1), and islet distribution of small foci (n = 3) may
have compromised visualization on MRI. Regarding
the relationship between the tumor location and MRI
visibility, previous studies showed the lack of add-
itional benefit of DCE-MRI and the difficulty of can-
cer detection in the transition zone [18, 19]. In the
present study, as shown in Table 2, although the
tumor location was not associated with visibility on
3-T MRI, our sample size was too small to draw a
definitive conclusion, and we agree that the co-
existing prostatic hyperplasia might compromise can-
cer detection in the transition zone.
Our study has several potential limitations. Firstly, this
was a small retrospective study. There was a selection
bias in that only patients undergoing prostatectomy were
enrolled. As described above, because all MR images
were reviewed in consensus by two radiologists during a
single session, we do not have data on inter- or intraob-
server variability of the Likert scale. The lack of an
endorectal coil may have influenced our observations.
Furthermore, in cases undergoing MRI evaluation after
biopsy, post-biopsy hemorrhage might have resulted in
difficulty of tumor detection. It remains unknown
whether the results would be reproducible in a different
institute with a reader with a different experience level.
Further validation studies are warranted to evaluate
whether a scoring system including a Likert scale can
become a common language among physicians treating
prostate carcinoma patients in daily clinical practice.
Conclusion
Each Likert scale well reflected the corresponding tu-
mor’s volume and Gleason score. Our observations show
that “scale 3 or higher” could be a useful threshold to
predict clinically significant carcinoma when considering
treatment options.
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